Selling supplements in China: SAMR, Blue Hat, and the CBEC route explained

China is the world's second-largest health supplement market and one of the most complex to enter. For foreign brands, there are two fundamentally different paths to market, and choosing the wrong one adds years and costs that most brands aren't expecting.

The two routes to market

Route 1: Domestic registration via SAMR (Blue Hat)

The State Administration for Market Regulation (SAMR) governs the domestic health food registration system in China. Products sold through domestic retail channels require a Blue Hat registration. Blue Hat registration is administered by the National Medical Products Administration (NMPA) on behalf of SAMR, and it's one of the most demanding registration processes globally: full clinical or technical dossier required, only approved health functions from a permitted list can be claimed, testing and verification requirements are extensive, a Chinese sponsor entity is required, timeline typically 3 to 5 years for foreign products, and cost often US$500K to US$1M or more.

The Blue Hat is the gold standard for widespread domestic distribution, but its cost and timeline put it out of reach for most brands at market entry stage.

Route 2: Cross-Border E-Commerce (CBEC)

CBEC allows foreign brands to sell directly to Chinese consumers via bonded warehouse platforms (primarily Tmall Global and JD Worldwide) without full Blue Hat registration. No pre-market registration is required for most categories. Products are sold under the brand's home country registration, stored in bonded warehouses in China's free trade zones, and purchased directly by Chinese consumers from the overseas store. Faster to market (weeks to months vs years) and lower upfront cost.

The limitations: CBEC restricts distribution to online channels only. You cannot sell through physical retail, hospitals, or domestic offline channels on CBEC status. The regulatory environment can also shift: China has updated CBEC rules periodically and some product categories have been moved off the positive list.

GB 7718: the labelling update brands are missing

Whether on Blue Hat or CBEC, food labelling in China is governed by GB 7718. The 2025 update (effective March 2027) introduces changes to mandatory labelling that brands need to plan for now: new ingredient declaration format, updated allergen labelling obligations, revised nutrition labelling thresholds, and changes to front-of-pack declaration requirements. Brands currently on CBEC with Chinese-language labels need to plan a label update cycle before March 2027.

The 2025 SAMR livestreaming restrictions

In 2025, SAMR implemented significant restrictions on health food marketing via KOL (Key Opinion Leader) livestreaming on platforms like Douyin (TikTok China) and Taobao Live. The restrictions limit what claims can be made via livestream and who can make them. For brands reliant on livestreaming as a CBEC sales channel, this requires a review of marketing strategy and claim compliance for China specifically.

What to think about before entering China

CBEC first is the right starting point for most foreign brands: lower risk, faster validation, and real consumer demand data before committing to Blue Hat costs. Chinese-language labelling is required even for CBEC products, so invest in proper GB 7718-compliant labels from the start. Claims strategy for China needs separate development: health function claims permitted in Australia, the US, or Europe are often not in China's approved list.

Taama's China coverage is coming soon, covering SAMR health food classification, CBEC requirements, and GB 7718 label compliance. Register interest